ACRDF:OTC-Acreage Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 1.46

Change

-0.09 (-5.81)%

Market Cap

USD 0.14B

Volume

1.60K

Avg Analyst Target

USD 1.36 (-6.85%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACRDF Stock Forecast & Price:
Based on the Acreage Holdings Inc stock forecasts from 1 analysts, the average analyst target price for Acreage Holdings Inc is USD 1.36 over the next 12 months. Acreage Holdings Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Acreage Holdings Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Acreage Holdings Inc’s stock price was USD 1.46. Acreage Holdings Inc’s stock price has changed by -6.71% over the past week, +11.45% over the past month and -3.95% over the last year.

About Acreage Holdings Inc (ACRDF:OTC)

Acreage Holdings, Inc., formerly High Street Capital Partners, is a principal investment firm specializing in cannabis industry. Acreage Holdings, Inc. was founded in 2014 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY Merck KGaA ADR

-0.66 (-1.82%)

USD79.59B 21.96 13.53
MKGAF MERCK Kommanditgesellschaft au..

-4.12 (-2.23%)

USD79.59B 21.69 13.53
TKPHF Takeda Pharmaceutical Co. Ltd.

+0.07 (+0.24%)

USD45.25B 29.56 0.07
HLNCF Haleon plc

N/A

USD31.40B 18.89 31.12
ESALF Eisai Co. Ltd

-3.20 (-4.71%)

USD22.04B 83.95 0.43
ESALY Eisai Co Ltd ADR

-0.35 (-0.54%)

USD18.72B 80.37 0.43
SGIOF Shionogi & Co. Ltd

-0.50 (-0.99%)

USD15.17B 17.88 0.07
SGIOY Shionogi & Co Ltd ADR

-0.07 (-0.52%)

USD15.11B 17.73 0.07
GNHAF Vifor Pharma AG

N/A

USD11.76B 80.92 17.53
SFOSF Shanghai Fosun Pharmaceutical ..

+0.10 (+3.00%)

USD11.75B 15.85 2.46

ETFs Containing ACRDF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.79% 92% A- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.79% 90% A- 86% B
Trailing 12 Months  
Capital Gain -4.67% 89% B+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.67% 88% B+ 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.90% 30% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.90% 30% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 25.06% 92% A- 76% C
Risk Adjusted Return -99.37% 12% F 3% F
Market Capitalization 0.14B 83% B 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.02 52% F 61% D-
Price / Cash Flow Ratio -3.38 73% C 73% C
EV/EBITDA -11.74 91% A- 88% B+
Management Effectiveness  
Return on Equity -47.54% 52% F 22% F
Return on Invested Capital -16.43% 50% F 26% F
Return on Assets -0.62% 79% C+ 50% F
Debt to Equity Ratio 85.75% 10% F 19% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.51 13% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.